Cargando…
The sialyl-glycolipid stage-specific embryonic antigen 4 marks a subpopulation of chemotherapy-resistant breast cancer cells with mesenchymal features
INTRODUCTION: Chemotherapy resistance resulting in incomplete pathologic response is associated with high risk of metastasis and early relapse in breast cancer. The aim of this study was to identify and evaluate biomarkers of treatment-resistant tumor cells. METHODS: We performed a cell surface mark...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4660783/ https://www.ncbi.nlm.nih.gov/pubmed/26607327 http://dx.doi.org/10.1186/s13058-015-0652-6 |
_version_ | 1782402872942526464 |
---|---|
author | Aloia, Andrea Petrova, Evgeniya Tomiuk, Stefan Bissels, Ute Déas, Olivier Saini, Massimo Zickgraf, Franziska Maria Wagner, Steve Spaich, Saskia Sütterlin, Marc Schneeweiss, Andreas Reitberger, Manuel Rüberg, Silvia Gerstmayer, Bernhard Agorku, David Knöbel, Sebastian Terranegra, Annalisa Falleni, Monica Soldati, Laura Sprick, Martin Ronald Trumpp, Andreas Judde, Jean-Gabriel Bosio, Andreas Cairo, Stefano Hardt, Olaf |
author_facet | Aloia, Andrea Petrova, Evgeniya Tomiuk, Stefan Bissels, Ute Déas, Olivier Saini, Massimo Zickgraf, Franziska Maria Wagner, Steve Spaich, Saskia Sütterlin, Marc Schneeweiss, Andreas Reitberger, Manuel Rüberg, Silvia Gerstmayer, Bernhard Agorku, David Knöbel, Sebastian Terranegra, Annalisa Falleni, Monica Soldati, Laura Sprick, Martin Ronald Trumpp, Andreas Judde, Jean-Gabriel Bosio, Andreas Cairo, Stefano Hardt, Olaf |
author_sort | Aloia, Andrea |
collection | PubMed |
description | INTRODUCTION: Chemotherapy resistance resulting in incomplete pathologic response is associated with high risk of metastasis and early relapse in breast cancer. The aim of this study was to identify and evaluate biomarkers of treatment-resistant tumor cells. METHODS: We performed a cell surface marker screen in triple-negative breast cancer patient-derived xenograft models treated with standard care genotoxic chemotherapy. Global expression profiling was used to further characterize the identified treatment-resistant subpopulations. RESULTS: High expression of sialyl-glycolipid stage-specific embryonic antigen 4 (SSEA4) was found in residual tumor cells surviving chemotherapy and in samples from metastatic patients who relapsed after neoadjuvant chemotherapy. Gene and microRNA (miRNA) expression profiling linked SSEA4 positivity with a mesenchymal phenotype and a deregulation of drug resistance pathways. Functional assays demonstrated a direct link between epithelial–mesenchymal transition (EMT) and SSEA4 expression. Interestingly, SSEA4 expression, EMT, and drug resistance seemed to be regulated posttranscriptionally. Finally, high expression of CMP-N-acetylneuraminate-β-galactosamide-α-2,3-sialyltransferase 2 (ST3GAL2), the rate-limiting enzyme of SSEA4 synthesis, was found to be associated with poor clinical outcome in breast and ovarian cancer patients treated with chemotherapy. CONCLUSIONS: In this study, we identified SSEA4 as highly expressed in a subpopulation of tumor cells resistant to multiple commonly used chemotherapy drugs, as well as ST3GAL2, the rate-limiting enzyme of SSEA4 synthesis, as a predictive marker of poor outcome for breast and ovarian cancer patients undergoing chemotherapy. Both biomarkers and additionally identified regulatory miRNAs may be used to further understand chemoresistance, to stratify patient groups in order to avoid ineffective and painful therapies, and to develop alternative treatment regimens for breast cancer patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13058-015-0652-6) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4660783 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-46607832015-11-27 The sialyl-glycolipid stage-specific embryonic antigen 4 marks a subpopulation of chemotherapy-resistant breast cancer cells with mesenchymal features Aloia, Andrea Petrova, Evgeniya Tomiuk, Stefan Bissels, Ute Déas, Olivier Saini, Massimo Zickgraf, Franziska Maria Wagner, Steve Spaich, Saskia Sütterlin, Marc Schneeweiss, Andreas Reitberger, Manuel Rüberg, Silvia Gerstmayer, Bernhard Agorku, David Knöbel, Sebastian Terranegra, Annalisa Falleni, Monica Soldati, Laura Sprick, Martin Ronald Trumpp, Andreas Judde, Jean-Gabriel Bosio, Andreas Cairo, Stefano Hardt, Olaf Breast Cancer Res Research Article INTRODUCTION: Chemotherapy resistance resulting in incomplete pathologic response is associated with high risk of metastasis and early relapse in breast cancer. The aim of this study was to identify and evaluate biomarkers of treatment-resistant tumor cells. METHODS: We performed a cell surface marker screen in triple-negative breast cancer patient-derived xenograft models treated with standard care genotoxic chemotherapy. Global expression profiling was used to further characterize the identified treatment-resistant subpopulations. RESULTS: High expression of sialyl-glycolipid stage-specific embryonic antigen 4 (SSEA4) was found in residual tumor cells surviving chemotherapy and in samples from metastatic patients who relapsed after neoadjuvant chemotherapy. Gene and microRNA (miRNA) expression profiling linked SSEA4 positivity with a mesenchymal phenotype and a deregulation of drug resistance pathways. Functional assays demonstrated a direct link between epithelial–mesenchymal transition (EMT) and SSEA4 expression. Interestingly, SSEA4 expression, EMT, and drug resistance seemed to be regulated posttranscriptionally. Finally, high expression of CMP-N-acetylneuraminate-β-galactosamide-α-2,3-sialyltransferase 2 (ST3GAL2), the rate-limiting enzyme of SSEA4 synthesis, was found to be associated with poor clinical outcome in breast and ovarian cancer patients treated with chemotherapy. CONCLUSIONS: In this study, we identified SSEA4 as highly expressed in a subpopulation of tumor cells resistant to multiple commonly used chemotherapy drugs, as well as ST3GAL2, the rate-limiting enzyme of SSEA4 synthesis, as a predictive marker of poor outcome for breast and ovarian cancer patients undergoing chemotherapy. Both biomarkers and additionally identified regulatory miRNAs may be used to further understand chemoresistance, to stratify patient groups in order to avoid ineffective and painful therapies, and to develop alternative treatment regimens for breast cancer patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13058-015-0652-6) contains supplementary material, which is available to authorized users. BioMed Central 2015-11-25 2015 /pmc/articles/PMC4660783/ /pubmed/26607327 http://dx.doi.org/10.1186/s13058-015-0652-6 Text en © Aloia et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Aloia, Andrea Petrova, Evgeniya Tomiuk, Stefan Bissels, Ute Déas, Olivier Saini, Massimo Zickgraf, Franziska Maria Wagner, Steve Spaich, Saskia Sütterlin, Marc Schneeweiss, Andreas Reitberger, Manuel Rüberg, Silvia Gerstmayer, Bernhard Agorku, David Knöbel, Sebastian Terranegra, Annalisa Falleni, Monica Soldati, Laura Sprick, Martin Ronald Trumpp, Andreas Judde, Jean-Gabriel Bosio, Andreas Cairo, Stefano Hardt, Olaf The sialyl-glycolipid stage-specific embryonic antigen 4 marks a subpopulation of chemotherapy-resistant breast cancer cells with mesenchymal features |
title | The sialyl-glycolipid stage-specific embryonic antigen 4 marks a subpopulation of chemotherapy-resistant breast cancer cells with mesenchymal features |
title_full | The sialyl-glycolipid stage-specific embryonic antigen 4 marks a subpopulation of chemotherapy-resistant breast cancer cells with mesenchymal features |
title_fullStr | The sialyl-glycolipid stage-specific embryonic antigen 4 marks a subpopulation of chemotherapy-resistant breast cancer cells with mesenchymal features |
title_full_unstemmed | The sialyl-glycolipid stage-specific embryonic antigen 4 marks a subpopulation of chemotherapy-resistant breast cancer cells with mesenchymal features |
title_short | The sialyl-glycolipid stage-specific embryonic antigen 4 marks a subpopulation of chemotherapy-resistant breast cancer cells with mesenchymal features |
title_sort | sialyl-glycolipid stage-specific embryonic antigen 4 marks a subpopulation of chemotherapy-resistant breast cancer cells with mesenchymal features |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4660783/ https://www.ncbi.nlm.nih.gov/pubmed/26607327 http://dx.doi.org/10.1186/s13058-015-0652-6 |
work_keys_str_mv | AT aloiaandrea thesialylglycolipidstagespecificembryonicantigen4marksasubpopulationofchemotherapyresistantbreastcancercellswithmesenchymalfeatures AT petrovaevgeniya thesialylglycolipidstagespecificembryonicantigen4marksasubpopulationofchemotherapyresistantbreastcancercellswithmesenchymalfeatures AT tomiukstefan thesialylglycolipidstagespecificembryonicantigen4marksasubpopulationofchemotherapyresistantbreastcancercellswithmesenchymalfeatures AT bisselsute thesialylglycolipidstagespecificembryonicantigen4marksasubpopulationofchemotherapyresistantbreastcancercellswithmesenchymalfeatures AT deasolivier thesialylglycolipidstagespecificembryonicantigen4marksasubpopulationofchemotherapyresistantbreastcancercellswithmesenchymalfeatures AT sainimassimo thesialylglycolipidstagespecificembryonicantigen4marksasubpopulationofchemotherapyresistantbreastcancercellswithmesenchymalfeatures AT zickgraffranziskamaria thesialylglycolipidstagespecificembryonicantigen4marksasubpopulationofchemotherapyresistantbreastcancercellswithmesenchymalfeatures AT wagnersteve thesialylglycolipidstagespecificembryonicantigen4marksasubpopulationofchemotherapyresistantbreastcancercellswithmesenchymalfeatures AT spaichsaskia thesialylglycolipidstagespecificembryonicantigen4marksasubpopulationofchemotherapyresistantbreastcancercellswithmesenchymalfeatures AT sutterlinmarc thesialylglycolipidstagespecificembryonicantigen4marksasubpopulationofchemotherapyresistantbreastcancercellswithmesenchymalfeatures AT schneeweissandreas thesialylglycolipidstagespecificembryonicantigen4marksasubpopulationofchemotherapyresistantbreastcancercellswithmesenchymalfeatures AT reitbergermanuel thesialylglycolipidstagespecificembryonicantigen4marksasubpopulationofchemotherapyresistantbreastcancercellswithmesenchymalfeatures AT rubergsilvia thesialylglycolipidstagespecificembryonicantigen4marksasubpopulationofchemotherapyresistantbreastcancercellswithmesenchymalfeatures AT gerstmayerbernhard thesialylglycolipidstagespecificembryonicantigen4marksasubpopulationofchemotherapyresistantbreastcancercellswithmesenchymalfeatures AT agorkudavid thesialylglycolipidstagespecificembryonicantigen4marksasubpopulationofchemotherapyresistantbreastcancercellswithmesenchymalfeatures AT knobelsebastian thesialylglycolipidstagespecificembryonicantigen4marksasubpopulationofchemotherapyresistantbreastcancercellswithmesenchymalfeatures AT terranegraannalisa thesialylglycolipidstagespecificembryonicantigen4marksasubpopulationofchemotherapyresistantbreastcancercellswithmesenchymalfeatures AT fallenimonica thesialylglycolipidstagespecificembryonicantigen4marksasubpopulationofchemotherapyresistantbreastcancercellswithmesenchymalfeatures AT soldatilaura thesialylglycolipidstagespecificembryonicantigen4marksasubpopulationofchemotherapyresistantbreastcancercellswithmesenchymalfeatures AT sprickmartinronald thesialylglycolipidstagespecificembryonicantigen4marksasubpopulationofchemotherapyresistantbreastcancercellswithmesenchymalfeatures AT trumppandreas thesialylglycolipidstagespecificembryonicantigen4marksasubpopulationofchemotherapyresistantbreastcancercellswithmesenchymalfeatures AT juddejeangabriel thesialylglycolipidstagespecificembryonicantigen4marksasubpopulationofchemotherapyresistantbreastcancercellswithmesenchymalfeatures AT bosioandreas thesialylglycolipidstagespecificembryonicantigen4marksasubpopulationofchemotherapyresistantbreastcancercellswithmesenchymalfeatures AT cairostefano thesialylglycolipidstagespecificembryonicantigen4marksasubpopulationofchemotherapyresistantbreastcancercellswithmesenchymalfeatures AT hardtolaf thesialylglycolipidstagespecificembryonicantigen4marksasubpopulationofchemotherapyresistantbreastcancercellswithmesenchymalfeatures AT aloiaandrea sialylglycolipidstagespecificembryonicantigen4marksasubpopulationofchemotherapyresistantbreastcancercellswithmesenchymalfeatures AT petrovaevgeniya sialylglycolipidstagespecificembryonicantigen4marksasubpopulationofchemotherapyresistantbreastcancercellswithmesenchymalfeatures AT tomiukstefan sialylglycolipidstagespecificembryonicantigen4marksasubpopulationofchemotherapyresistantbreastcancercellswithmesenchymalfeatures AT bisselsute sialylglycolipidstagespecificembryonicantigen4marksasubpopulationofchemotherapyresistantbreastcancercellswithmesenchymalfeatures AT deasolivier sialylglycolipidstagespecificembryonicantigen4marksasubpopulationofchemotherapyresistantbreastcancercellswithmesenchymalfeatures AT sainimassimo sialylglycolipidstagespecificembryonicantigen4marksasubpopulationofchemotherapyresistantbreastcancercellswithmesenchymalfeatures AT zickgraffranziskamaria sialylglycolipidstagespecificembryonicantigen4marksasubpopulationofchemotherapyresistantbreastcancercellswithmesenchymalfeatures AT wagnersteve sialylglycolipidstagespecificembryonicantigen4marksasubpopulationofchemotherapyresistantbreastcancercellswithmesenchymalfeatures AT spaichsaskia sialylglycolipidstagespecificembryonicantigen4marksasubpopulationofchemotherapyresistantbreastcancercellswithmesenchymalfeatures AT sutterlinmarc sialylglycolipidstagespecificembryonicantigen4marksasubpopulationofchemotherapyresistantbreastcancercellswithmesenchymalfeatures AT schneeweissandreas sialylglycolipidstagespecificembryonicantigen4marksasubpopulationofchemotherapyresistantbreastcancercellswithmesenchymalfeatures AT reitbergermanuel sialylglycolipidstagespecificembryonicantigen4marksasubpopulationofchemotherapyresistantbreastcancercellswithmesenchymalfeatures AT rubergsilvia sialylglycolipidstagespecificembryonicantigen4marksasubpopulationofchemotherapyresistantbreastcancercellswithmesenchymalfeatures AT gerstmayerbernhard sialylglycolipidstagespecificembryonicantigen4marksasubpopulationofchemotherapyresistantbreastcancercellswithmesenchymalfeatures AT agorkudavid sialylglycolipidstagespecificembryonicantigen4marksasubpopulationofchemotherapyresistantbreastcancercellswithmesenchymalfeatures AT knobelsebastian sialylglycolipidstagespecificembryonicantigen4marksasubpopulationofchemotherapyresistantbreastcancercellswithmesenchymalfeatures AT terranegraannalisa sialylglycolipidstagespecificembryonicantigen4marksasubpopulationofchemotherapyresistantbreastcancercellswithmesenchymalfeatures AT fallenimonica sialylglycolipidstagespecificembryonicantigen4marksasubpopulationofchemotherapyresistantbreastcancercellswithmesenchymalfeatures AT soldatilaura sialylglycolipidstagespecificembryonicantigen4marksasubpopulationofchemotherapyresistantbreastcancercellswithmesenchymalfeatures AT sprickmartinronald sialylglycolipidstagespecificembryonicantigen4marksasubpopulationofchemotherapyresistantbreastcancercellswithmesenchymalfeatures AT trumppandreas sialylglycolipidstagespecificembryonicantigen4marksasubpopulationofchemotherapyresistantbreastcancercellswithmesenchymalfeatures AT juddejeangabriel sialylglycolipidstagespecificembryonicantigen4marksasubpopulationofchemotherapyresistantbreastcancercellswithmesenchymalfeatures AT bosioandreas sialylglycolipidstagespecificembryonicantigen4marksasubpopulationofchemotherapyresistantbreastcancercellswithmesenchymalfeatures AT cairostefano sialylglycolipidstagespecificembryonicantigen4marksasubpopulationofchemotherapyresistantbreastcancercellswithmesenchymalfeatures AT hardtolaf sialylglycolipidstagespecificembryonicantigen4marksasubpopulationofchemotherapyresistantbreastcancercellswithmesenchymalfeatures |